ClinicalTrials.gg
RecruitingNCT07044310Updated Aug 10, 2026

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

A Phase 2 interventional study of Biospecimen Collection and Bone Mineral Density Test in Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage II Breast Cancer AJCC v8, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Breast Carcinoma In Situ by Mayo Clinic — 3 open to participants now, 3 under way, none of them phase 3. Breast Carcinoma In Situ · Mayo Clinic.

Started
2025
the only one that year
Phase 2
5 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Breast Carcinoma In Situ by Mayo Clinic, this one is the only one that started in 2025, is one of 5 in phase 2, and was the 14th registered.

Breast Carcinoma In Situ

190 studies on the registry are indexed under Breast Carcinoma In Situ; 25 are open to participants now.

Browse Breast Carcinoma In Situ studies →

Open to participants now

3 of the 14 studies in Breast Carcinoma In Situ by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 23 Breast Carcinoma In Situ studies recruiting now, 17 (74%) set no upper age limit and 4 (17%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Breast Carcinoma In Situ by Mayo Clinic, or all of them as a file.
02

Study summary

This phase II trial tests how well a probiotic, WBF-038, works in preventing bone loss in patients with early-stage hormone receptor-positive breast cancer who are starting treatment with aromatase inhibitors. Aromatase inhibitors are a drug that blocks the activity of an enzyme called aromatase, which the body uses to make estrogen in the ovaries and other tissues. Blocking aromatase lowers the amount of estrogen made by the body, which may stop the growth of cancer cells that need estrogen to grow. Aromatase inhibitors are used to treat some types of breast cancer or to keep it from coming back. Aromatase inhibitors can affect bone health, weight, blood sugar, and waist size. WBF-038 is a combination of both prebiotics and probiotics, designed to improve metabolic health. Giving WBF-038 may improve bone turnover, bone health, blood sugar, weight, and waist circumference in patients with early-stage hormone receptor-positive breast cancer starting on adjuvant endocrine therapy with an aromatase inhibitor.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the median percent change from baseline (prior to the start of an aromatase inhibitor [AI]) at 15 months in C-terminal telopeptide of type 1 collagen (CTx) in early-stage breast cancer patients who receive WBF-038 treatment for 12 months starting at 3 months post-baseline.

SECONDARY OBJECTIVES:

I. To evaluate the median percent change from baseline (prior to the start of an AI) at 15 months in the lumbar spine and hip bone mineral density in early-stage breast cancer patients who receive WBF-038 treatment for 12 months starting at 3 months post-baseline.

II. To evaluate safety and risk of fracture associated with WBF-038.

EXPLORATORY OBJECTIVES:

I. To evaluate changes from baseline (prior to the start of an AI) over time in CTx, alkaline phosphatase (ALK), fasting blood sugar (FBS), hemoglobin A1C (HbA1C), and Procollagen I Intact N-Terminal (P1NP) at 3, 6, 15, and 18 months post-baseline.

II. To evaluate changes from baseline (prior to the start of an AI) over time in weight and waist circumference at 3, 6, 15, and 18 months post-baseline.

III. To evaluate changes in the cytokine profile over time. IV. To evaluate the association between stool microbiome, stool short-chain fatty acid (SCFA), and serum SCFA and changes over time in CTx and lumbar spine and hip bone mineral density.

V. To evaluate changes over time in AI-associated musculoskeletal symptoms (AIMSS) with patient-reported outcomes (PRO) using the Stanford Health Assessment Questionnaire (HAQ) and pain visual analog scale (VAS).

OUTLINE:

Patients receive WBF-038 orally (PO) once daily (QD) for 365 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and bone mineral density (BMD) test at screening and on study.

After completion of study intervention, patients are followed up at 90 days.

03

Conditions studied

  • Anatomic Stage 0 Breast Cancer AJCC v8
  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Hormone Receptor-Positive Breast Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female age ≥ 18 years
  • (ECOG) performance status 0, 1, or 2
  • confirmed anatomical stage 0-III hormone receptor-positive breast cancer
  • Will be starting on an aromatase inhibitor (letrozole, anastrozole, or exemestane) ± ovarian function suppression (OFS) per treating physician's discretion
  • (ANC) ≥ 1000/mm\^3 (prior to registration)
  • count ≥ 75,000/mm\^3 (prior to registration)
  • ≥ 9.0 g/dL (prior to registration)
  • Creatinine ≤ 2 x (ULN) (prior to registration)
  • Serum glutamic-oxaloacetic transaminase () (aspartate aminotransferase [AST]) ≤ 2 x ULN (prior to registration)
  • Albumin ≥ 3 g/dL (prior to registration)
  • Willing and able to provide research stool and blood samples
  • Negative serum pregnancy test done ≤ 7 days prior to registration, for women of only (\< 60 years old with intact uterus)
  • Capable of providing valid
  • Willing to return to enrolling institution for all study visits (blood draws, etc)

Exclusion criteria

Exclusion Criteria:

  • Requires prolonged systemic antibiotic therapy for other conditions and recent systemic antibiotic ≤ 14 days prior to registration
  • Fecal microbiota transplant (FMT) ≤ 6 months prior to registration
  • FMT with an associated serious adverse event related to the FMT product or procedure
  • Co-morbid systemic illnesses or other severe concurrent diseases which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of over-the-counter probiotics
  • patients including patients known to be positive or those on chronic > 20 mg prednisone a day or prednisone-equivalent. Note: Must be off systemic steroids ≥ 90 days prior to registration. However, topical steroids, inhalants, or steroid eye drops are permitted
  • History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis
  • History of chronic diarrhea
  • History of celiac disease
  • Currently has a colostomy
  • Intraabdominal surgery related to gastrointestinal tract ≤ 60 days prior to registration
  • Evidence of active, severe colitis
  • History of short gut syndrome or motility disorders
  • Requires the daily use of medications to manage bowel hypermotility, such as imodium or lomotil
  • Active disease that has required systemic treatment in the ≤ 30 days (i.e., with the use of disease-modifying agents, corticosteroids, or immunosuppressive products) prior to registration. Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Patients with vitiligo, Graves' disease, or psoriasis not requiring systemic treatment ≤ 30 days prior to registration are not excluded
  • History of osteoporosis or hyperparathyroidism
  • History of untreated vitamin D deficiency
  • Receiving or will receive bisphosphonates during study period (alendronate, risedronate, ibandronate, pamidronate, or zolendronic acid) or denosumab
  • Patients who received oral bisphosphonate within ≤ 12 weeks, intravenous (IV) zoledronic acid (Reclast) ≤ 52 weeks, or denosumab ≤ 24 weeks will also be excluded
  • Known to any component of study product (including known inulin intolerance)
  • Known hypersensitivity to > 4 antimicrobial therapies against akkermansia muciniphila, clostridium beijerinckii, clostridium butyricum, anaerobutyricum hallii, including penicillin, piperacillin, tetracycline, amoxicillin, or ampicillin
  • Known hypersensitivity to > 4 first line antimicrobial therapies against bifidobacterium infantis Bi-26TM, including gentamicin, kanamycin, streptomycin, tetracycline, erythromycin, clindamycin, ampicillin, vancomycin
  • Received an experimental product ≤ 30 days prior to registration
  • Receiving or will receive CDK 4/6 inhibitor (abemaciclib, ribociclib, or palbociclib)
  • Received chemotherapy ≤ 30 days prior to registration
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Supportive care (WBF-038)

    Patients receive WBF-038 PO QD for 365 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and BMD test at screening and on study.

    Procedure: Biospecimen Collection · Procedure: Bone Mineral Density Test · Other: Questionnaire Administration · Drug: WBF-038

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Mineral Density Test

    Undergo BMD

    Also known as: BMD, bone density, Bone Density Test, bone mass, Bone Mineral Density

  • OtherQuestionnaire Administration

    Ancillary studies

  • DrugWBF-038

    Given WBF-038 PO

    Also known as: Akkermansia muciniphila/Anaerobutyricum hallii/Bifidobacterium infantis/Clostridium beijerinckii/Clostridium butyricum/Inulin WBF-038, Pendulum WBF-038 (SY), Probiotic/Prebiotic Formulation WBF-038 (SY), Synbiotic Formulation WBF-038 (SY), WBF 038 (CN), WBF-038 (CN), WBF038 (CN)

06

What researchers measure

Primary outcomes

  1. Change in C-terminal telopeptide of type 1 collagen (CTx)

    Assessed by standard lab tests at baseline (at study enrollment/eligibility assessment before any therapy) followed by 6 study visits. Participants receive aromatase Inhibitor (AI) therapy followed by a one-year course of probiotic WBF-038.

    Time frame: Baseline; 90 days after start of AI therapy (before beginning WBF-038); 14 days after start of WBF-038; 90 days after start of WBF-038; 180 days after start of WBF-038; 365 days after start of WBF-038; 90 days after stopping WBF-038

Secondary outcomes

  1. Change in lumbar spine mineral density

    Will be measured by central dual energy x-ray absorptiometry. Participants receive aromatase Inhibitor (AI) therapy followed by a one-year course of probiotic WBF-038.

    Time frame: Baseline; 365 days after start of WBF-038

  2. Change in hip bone mineral density

    Will be measured by central dual energy x-ray absorptiometry. Participants receive aromatase Inhibitor (AI) therapy followed by a one-year course of probiotic WBF-038.

    Time frame: Baseline; 365 days after start of WBF-038

  3. Incidence of adverse events

    Will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: Baseline; 90 days after start of AI therapy (before beginning WBF-038); 90 days after start of WBF-038; 365 days after starting WBF-038; 90 days after stopping WBF-038;

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 21 phase 2 interventional studies under Breast Carcinoma In Situ, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jun 29, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Jul 25, 2027
CompletionEst.
Jul 25, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07044310
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Jul 25, 2025
Primary completion
Jul 25, 2027 (estimated)
Completion
Jul 25, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Saranya Chumsri, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion